Evolocumab

Details

Files

Generic Name:

Evolocumab

Project Status:

Complete

Therapeutic Area:

Primary hyperlipidemia; mixed dyslipidemia

Manufacturer:

Amgen Canada Inc.

Call for patient/clinician input open:

June 4, 2015

Brand Name:

Repatha

Project Line:

Reimbursement Review

Project Number:

SR0441-000

Call for patient/clinician input closed:

July 24, 2015

NOC Status at Filing:

Pre NOC

Performance Metric:

N/A delay outside our control - Application held awaiting decision by Health Canada

Submission Type:

Initial

Indications:

Primary hyperlipidemia and mixed dyslipidemia

Recommendation Type:

List with clinical criteria and/or conditions

Final Recommendation:

February 19, 2016

Last Updated : June 4, 2015